Cargando…

Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients

BACKGROUND: Solid-phase assays to investigate the complement-activating capacity of HLA antibodies have been utilized to optimize organ allocation and improve transplant outcomes. The clinical utility of C1q/C3d-binding characteristics of de novo donor-specific anti-HLA antibodies (dnDSA) associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatapudi, Vasishta S., Kopchaliiska, Dessislava, da Gente, Gilberto J., Buenaventura, Owen F., Singh, Manpreet, Laszik, Zoltan, Adey, Deborah B., Rajalingam, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647455/
https://www.ncbi.nlm.nih.gov/pubmed/34848674
http://dx.doi.org/10.12659/AOT.934175
_version_ 1784610607984541696
author Tatapudi, Vasishta S.
Kopchaliiska, Dessislava
da Gente, Gilberto J.
Buenaventura, Owen F.
Singh, Manpreet
Laszik, Zoltan
Adey, Deborah B.
Rajalingam, Raja
author_facet Tatapudi, Vasishta S.
Kopchaliiska, Dessislava
da Gente, Gilberto J.
Buenaventura, Owen F.
Singh, Manpreet
Laszik, Zoltan
Adey, Deborah B.
Rajalingam, Raja
author_sort Tatapudi, Vasishta S.
collection PubMed
description BACKGROUND: Solid-phase assays to investigate the complement-activating capacity of HLA antibodies have been utilized to optimize organ allocation and improve transplant outcomes. The clinical utility of C1q/C3d-binding characteristics of de novo donor-specific anti-HLA antibodies (dnDSA) associated with C4d-positive antibody-mediated rejection (C4d(+) AMR) in kidney transplants (KTx) has not been defined. MATERIAL/METHODS: Sera from 120 KTx recipients that had dnDSA concurrent with protocol/cause biopsy (median 3.8 years after transplantation) were screened for C1q and C3d-binding dnDSA. The difference in the incidence of C4d(+) AMR between recipients with and without C1q/C3d-binding dnDSA was assessed. RESULTS: Over 86% of dnDSAs were class II antibodies. The immunodominant dnDSAs characterized by the highest median fluorescence intensity (MFI) in most recipients were HLA-DQ antibodies (67%). Most recipients (62%, n=74) had either C1q(+) (56%), C3d(+) (48%), or both C1q(+)C3d(+) (41.2%) dnDSA, while the remaining 38% were negative for both C1q and C3d. Of those with C1q(+)/C3d(+) dnDSA, 87% had high-MFI IgG (MFI=14144±5363 and 13932±5278, respectively), while 65% of C1q(−)C3d(−) dnDSA had low-MFI IgG (MFI=5970±3347). The incidence of C4d(+) AMR was significantly higher in recipients with C1q(+) (66%), C3d(+) (74%), and C1q(+)C3d(+) (72%) dnDSA than in those with C1q(−)C3d(−) dnDSA (30%) recipients. Recipients with C3d(+)/C1q(+) dnDSA had higher C4d(+) scores on biopsy. CONCLUSIONS: C1q(+)/C3d(+) dnDSA were associated with C4d(+) AMR and high-IgG MFI. Our data call into question the predictive utility of C1q/C3d-binding assays in identifying KTx recipients at risk of allograft failure. In conclusion, IgG MFI is sufficient for clinical management, and the C1q/C3d-assays with added cost do not provide any additional information.
format Online
Article
Text
id pubmed-8647455
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-86474552021-12-30 Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients Tatapudi, Vasishta S. Kopchaliiska, Dessislava da Gente, Gilberto J. Buenaventura, Owen F. Singh, Manpreet Laszik, Zoltan Adey, Deborah B. Rajalingam, Raja Ann Transplant Original Paper BACKGROUND: Solid-phase assays to investigate the complement-activating capacity of HLA antibodies have been utilized to optimize organ allocation and improve transplant outcomes. The clinical utility of C1q/C3d-binding characteristics of de novo donor-specific anti-HLA antibodies (dnDSA) associated with C4d-positive antibody-mediated rejection (C4d(+) AMR) in kidney transplants (KTx) has not been defined. MATERIAL/METHODS: Sera from 120 KTx recipients that had dnDSA concurrent with protocol/cause biopsy (median 3.8 years after transplantation) were screened for C1q and C3d-binding dnDSA. The difference in the incidence of C4d(+) AMR between recipients with and without C1q/C3d-binding dnDSA was assessed. RESULTS: Over 86% of dnDSAs were class II antibodies. The immunodominant dnDSAs characterized by the highest median fluorescence intensity (MFI) in most recipients were HLA-DQ antibodies (67%). Most recipients (62%, n=74) had either C1q(+) (56%), C3d(+) (48%), or both C1q(+)C3d(+) (41.2%) dnDSA, while the remaining 38% were negative for both C1q and C3d. Of those with C1q(+)/C3d(+) dnDSA, 87% had high-MFI IgG (MFI=14144±5363 and 13932±5278, respectively), while 65% of C1q(−)C3d(−) dnDSA had low-MFI IgG (MFI=5970±3347). The incidence of C4d(+) AMR was significantly higher in recipients with C1q(+) (66%), C3d(+) (74%), and C1q(+)C3d(+) (72%) dnDSA than in those with C1q(−)C3d(−) dnDSA (30%) recipients. Recipients with C3d(+)/C1q(+) dnDSA had higher C4d(+) scores on biopsy. CONCLUSIONS: C1q(+)/C3d(+) dnDSA were associated with C4d(+) AMR and high-IgG MFI. Our data call into question the predictive utility of C1q/C3d-binding assays in identifying KTx recipients at risk of allograft failure. In conclusion, IgG MFI is sufficient for clinical management, and the C1q/C3d-assays with added cost do not provide any additional information. International Scientific Literature, Inc. 2021-12-01 /pmc/articles/PMC8647455/ /pubmed/34848674 http://dx.doi.org/10.12659/AOT.934175 Text en © Ann Transplant, 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Original Paper
Tatapudi, Vasishta S.
Kopchaliiska, Dessislava
da Gente, Gilberto J.
Buenaventura, Owen F.
Singh, Manpreet
Laszik, Zoltan
Adey, Deborah B.
Rajalingam, Raja
Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients
title Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients
title_full Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients
title_fullStr Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients
title_full_unstemmed Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients
title_short Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients
title_sort solid-phase c1q/c3d fixing readouts correlate with high median fluorescence intensity (mfi) de novo donor-specific hla antibodies and c4d(+) antibody-mediated rejection in kidney transplant recipients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647455/
https://www.ncbi.nlm.nih.gov/pubmed/34848674
http://dx.doi.org/10.12659/AOT.934175
work_keys_str_mv AT tatapudivasishtas solidphasec1qc3dfixingreadoutscorrelatewithhighmedianfluorescenceintensitymfidenovodonorspecifichlaantibodiesandc4dantibodymediatedrejectioninkidneytransplantrecipients
AT kopchaliiskadessislava solidphasec1qc3dfixingreadoutscorrelatewithhighmedianfluorescenceintensitymfidenovodonorspecifichlaantibodiesandc4dantibodymediatedrejectioninkidneytransplantrecipients
AT dagentegilbertoj solidphasec1qc3dfixingreadoutscorrelatewithhighmedianfluorescenceintensitymfidenovodonorspecifichlaantibodiesandc4dantibodymediatedrejectioninkidneytransplantrecipients
AT buenaventuraowenf solidphasec1qc3dfixingreadoutscorrelatewithhighmedianfluorescenceintensitymfidenovodonorspecifichlaantibodiesandc4dantibodymediatedrejectioninkidneytransplantrecipients
AT singhmanpreet solidphasec1qc3dfixingreadoutscorrelatewithhighmedianfluorescenceintensitymfidenovodonorspecifichlaantibodiesandc4dantibodymediatedrejectioninkidneytransplantrecipients
AT laszikzoltan solidphasec1qc3dfixingreadoutscorrelatewithhighmedianfluorescenceintensitymfidenovodonorspecifichlaantibodiesandc4dantibodymediatedrejectioninkidneytransplantrecipients
AT adeydeborahb solidphasec1qc3dfixingreadoutscorrelatewithhighmedianfluorescenceintensitymfidenovodonorspecifichlaantibodiesandc4dantibodymediatedrejectioninkidneytransplantrecipients
AT rajalingamraja solidphasec1qc3dfixingreadoutscorrelatewithhighmedianfluorescenceintensitymfidenovodonorspecifichlaantibodiesandc4dantibodymediatedrejectioninkidneytransplantrecipients